/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Editas Medicine Inc.

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.35 0.1209(12.09%) EDIT at 04 Dec 2025 04:30 PM Biotechnology
Lowest Today 2.12
Highest Today 2.37
Today’s Open 2.14
Prev. Close 2.11
52 Week High 4.54
52 Week Low 0.91
Day’s Range: Low 2.12 High 2.37
52-Week Range: Low 0.91 High 4.54
1 day return -
1 Week return -1.45
1 month return -14.62
3 month return -5.96
6 month return +30.3
1 year return +19.44
3 year return -75.95
5 year return -93.14
10 year return -

Institutional Holdings

Vanguard Group Inc 7.96

BlackRock Inc 7.59

Vanguard Total Stock Mkt Idx Inv 2.82

iShares Russell 2000 ETF 2.30

Geode Capital Management, LLC 2.18

Millennium Management LLC 2.09

Vanguard Strategic Equity Inv 2.08

State Street Corp 2.05

Nuveen Quant Small Cap Equity R6 1.81

Morgan Stanley - Brokerage Accounts 1.58

Dimensional Fund Advisors, Inc. 1.56

Selectra J. Lamarck Biotech A 1.23

Bank of America Corp 1.20

JPMorgan Chase & Co 1.19

Two Sigma Investments LLC 1.08

Nuveen, LLC 1.06

Susquehanna International Group, LLP 1.05

Two Sigma Advisers, LLC 1.05

Renaissance Technologies Corp 0.99

Fidelity Small Cap Index 0.94

Woodline Partners LP 0.94

Vanguard Institutional Extnd Mkt Idx Tr 0.92

AQR Capital Management LLC 0.85

iShares Russell 2000 Value ETF 0.81

Charles Schwab Investment Management Inc 0.78

Northern Trust Corp 0.73

Goldman Sachs Group Inc 0.73

JPM Thematics Genetic Thrps C2 dist USD 0.73

Citadel Advisors Llc 0.71

Kennedy Micro Cap 0.63

Vanguard Strategic Small-Cap Equity Inv 0.61

iShares Biotechnology ETF 0.55

Fidelity Extended Market Index 0.46

Vanguard Russell 2000 ETF 0.45

Dimensional US Targeted Value ETF 0.42

Schwab US Small-Cap ETF™ 0.40

State St Russell Sm Cap® Indx SL Cl I 0.36

Vanguard Health Care ETF 0.28

Schwab Small Cap Index 0.24

Multi-Manager Small Cap Eq Strat Inst 0.23

Market Status

Strong Buy: 4

Buy: 1

Hold: 8

Sell: 2

Strong Sell: 0

Fundamentals

Market Cap 205.98 M

PB Ratio 17.4876

PE Ratio 0.0

Enterprise Value 89.26 M

Total Assets 341.59 M

Volume 1955479

Company Financials

Annual Revenue FY23:24610000 24.6M, FY22:19712000 19.7M, FY21:25544000 25.5M, FY20:90732000 90.7M, FY19:20531000 20.5M

Annual Profit FY23:null 0.0M, FY22:19712000 19.7M, FY21:25544000 25.5M, FY20:90732000 90.7M, FY19:20531000 20.5M

Annual Net worth FY23:-195083000 -195.1M, FY22:-204352000 -204.4M, FY21:-185107000 -185.1M, FY20:-109412000 -109.4M, FY19:-123466000 -123.5M

Quarterly Revenue Q3/2025:7543000 7.5M, Q2/2025:3578000 3.6M, Q1/2025:4658000 4.7M, Q3/2024:61000 0.1M, Q2/2024:513000 0.5M

Quarterly Profit Q3/2025:7543000 7.5M, Q2/2025:3578000 3.6M, Q1/2025:4658000 4.7M, Q3/2024:-1538000 -1.5M, Q2/2024:-907000 -0.9M

Quarterly Net worth Q3/2025:-25117000 -25.1M, Q2/2025:-53235000 -53.2M, Q1/2025:-76088000 -76.1M, Q3/2024:-62141000 -62.1M, Q2/2024:-67607000 -67.6M

Fund house & investment objective

Company Information Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Organisation Biotechnology

Employees 246

Industry Biotechnology

CEO Dr. Gilmore O'Neill M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow